Daily Newsletter

04 March 2024

Daily Newsletter

04 March 2024

Sandoz strengthens US biosimilar market with CIMERLI acquisition

CIMERLI is an approved biosimilar to the reference product LUCENTIS, indicated for the treatment of retinal diseases.

Vishnu Priyan March 04 2024

Sandoz has concluded the acquisition of the US biosimilar CIMERLI from Coherus BioSciences, marking a significant expansion of its ophthalmology and biosimilar expertise in the US market.

The transaction, valued at $170m in upfront cash, encompasses the full CIMERLI business, including a biologics licence application, product inventory, specialised commercial software, ophthalmology sales and field reimbursement talent.

CIMERLI, a US Food and Drug Administration (FDA)-approved biosimilar to the reference product LUCENTIS, is indicated for the treatment of retinal diseases. These can lead to significant vision loss and are among the top ten causes of disability in the country.

The biosimilar, which is an anti–vascular endothelial growth factor therapy, has been shown to help patients with retinal diseases maintain or improve their vision.

The acquisition was agreed by the companies in January 2023.

CIMERLI comes in 6mg/mL and 10mg/mL concentrations and is designed for injection.

It addresses retinal ailments such as diabetic macular oedema, diabetic retinopathy macular oedema after retinal vein occlusion, myopic choroidal neovascularisation, and neovascular (wet) age-related macular degeneration.

Approved by the FDA in August 2022 and launched two months later, CIMERLI met the regulator's standards of biosimilarities, including safety, efficacy and quality.

It is the first and only FDA-approved biosimilar interchangeable with LUCENTIS for all its indications.

Sandoz North America president Keren Haruvi stated: “Today, we further expand the Sandoz biosimilar portfolio while advancing our mission in the US of pioneering patient access to more affordable and much-needed medicines.

“With the addition of CIMERLI to our existing ophthalmology franchise, we can now offer even more treatment options for US patients with vision impairment and loss.”

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close